1. Home
  2. BMEA vs DWSN Comparison

BMEA vs DWSN Comparison

Compare BMEA & DWSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.52

Market Cap

107.7M

Sector

Health Care

ML Signal

HOLD

DWSN

Dawson Geophysical Company

HOLD

Current Price

$3.01

Market Cap

113.3M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
DWSN
Founded
2017
1952
Country
United States
United States
Employees
41
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
107.7M
113.3M
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
BMEA
DWSN
Price
$1.52
$3.01
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$8.86
N/A
AVG Volume (30 Days)
1.3M
277.4K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
69.19
53.85
EPS
N/A
N/A
Revenue
N/A
$145,773,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$1.08
52 Week High
$3.07
$5.54

Technical Indicators

Market Signals
Indicator
BMEA
DWSN
Relative Strength Index (RSI) 62.69 47.93
Support Level $1.22 $1.64
Resistance Level $1.66 $5.25
Average True Range (ATR) 0.13 0.63
MACD 0.03 -0.10
Stochastic Oscillator 86.54 32.82

Price Performance

Historical Comparison
BMEA
DWSN

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About DWSN Dawson Geophysical Company

Dawson Geophysical Co is a provider of onshore seismic data acquisition services with operations throughout the continental United States and Canada. The company acquires and processes 2 D, 3 D, and multi-component seismic data for clients, ranging from oil and gas companies to independent oil and gas operators for use in the onshore drilling and production of oil and natural gas as well as provides multi-client data libraries. It operates through a single segment being Contract seismic data acquisition and processing services. In addition, the company provides multi-component seismic data surveys which involve the recording of alternative seismic waves. Geographically, it generates maximum revenue from the United States.

Share on Social Networks: